» Articles » PMID: 38317820

Circulating MiR-21 Overexpression Correlates with PDCD4 and IL-10 in Systemic Lupus Erythematosus (SLE): A Promising Diagnostic and Prognostic Biomarker

Overview
Specialty Biochemistry
Date 2024 Feb 6
PMID 38317820
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition that affects multiple organs significantly impacts morbidity and mortality. The development of SLE is influenced by genetic predisposition and dysregulated immune response. Our objective was to investigate miR-21, IL-10, and PDCD4 expression in SLE patient plasma and analyze their correlations and potential diagnostic and prognostic values.

Methods: The study included 100 healthy subjects, 50 newly diagnosed (ND), and 50 under-treatment (UT) SLE patients. The patients were observed for 24 weeks to track relapses. miR-21 and PDCD4 gene expression levels were measured using real-time RT-PCR, and IL-10 production was measured using ELISA.

Results: miR-21 and IL-10 expression levels were significantly greater in SLE patients than in healthy subjects, with the highest levels observed in ND patients. PDCD4 expression was also significantly greater in SLE patients than in subjects, with the highest levels observed in UT patients. ROC curve analyses and Cox-Mantel Log-rank tests indicated miR-21, PDCD4, and IL-10 as proper diagnostic and prognostic biomarkers for SLE. The study also revealed a significant positive correlation between miR-21 and PDCD4 and IL-10 levels in SLE patients.

Conclusions: The studies suggest that dysregulation of miR-21, PDCD4, and IL-10 in patients with SLE may contribute to disease development and provides new diagnostic and prognostic markers. Additionally, the observed correlation between miR-21, PDCD4, and IL-10 levels in SLE patients signifies a potential interplay between these molecules.

Citing Articles

3,4 Dihydroxyphenylethanol May Inhibit Metastasis in HepG2 Cells by Influencing the Expression of miR-21 and Genes Associated with Metastasis.

Alaee M, Shahsavari G, Yazdi M, Hormozi M Rep Biochem Mol Biol. 2025; 13(2):254-262.

PMID: 39995649 PMC: 11847581. DOI: 10.61186/rbmb.13.2.254.


Role of MicroRNA-21 in Regulating Intracellular Pathways Associated With Phagocytosis in Human Macrophages: An In Vitro Study.

Anada N, Nakayama Y, Takeshita J, Kageyama K, Sakamoto H, Kamibayashi T Cureus. 2024; 16(7):e63736.

PMID: 39100039 PMC: 11295782. DOI: 10.7759/cureus.63736.

References
1.
Chun H, Chung J, Kim H, Yun J, Jeon J, Ye Y . Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27(5):461-6. DOI: 10.1007/s10875-007-9104-0. View

2.
Ahearn J, Liu C, Kao A, Manzi S . Biomarkers for systemic lupus erythematosus. Transl Res. 2012; 159(4):326-42. DOI: 10.1016/j.trsl.2012.01.021. View

3.
Garchow B, Bartulos Encinas O, Leung Y, Tsao P, Eisenberg R, Caricchio R . Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med. 2011; 3(10):605-15. PMC: 3258486. DOI: 10.1002/emmm.201100171. View

4.
Tang Z, Fang M, Wang J, Cai P, Wang P, Hu L . Clinical relevance of plasma miR-21 in new-onset systemic lupus erythematosus patients. J Clin Lab Anal. 2014; 28(6):446-51. PMC: 6807453. DOI: 10.1002/jcla.21708. View

5.
Danchenko N, Satia J, Anthony M . Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006; 15(5):308-18. DOI: 10.1191/0961203306lu2305xx. View